MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience

European Heart Journal

Volumn 20, Issue 10, 1999, Pages 725-741

  Meade, T ^a   Sleight, P ^a   Collins, R ^a   Armitage, J ^a   Parish, S ^a   Peto, R ^a   Youngman, L ^a   Buxton, M ^a   De Bono, D ^a   Fuller, J ^a   Keech, A ^a   Mansfield, A ^a   Pentecost, B ^a   Simpson, D ^a   Warlow, C ^a   O'Toole, L ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

Antioxidant vitamins; Cholesterol lowering; Coronary heart disease; Randomized trial; Simvastatin

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MUSCLE ENZYME; SIMVASTATIN;

ADULT; AGED; ARTERY OCCLUSION; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART PROTECTION; HEPATITIS; HIGH RISK POPULATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MUSCLE DISEASE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ADULT; AGED; ANTIOXIDANTS; APOLIPOPROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; SIMVASTATIN; TREATMENT OUTCOME; TRIGLYCERIDES; VITAMIN E;

EID: 0033135795     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1350     Document Type: Article

References (77)

1. Keys A. Seven Countries: A Multivariate Analysis of Health and Coronary Heart Disease. Harvard: Harvard University Press, 1980.
2. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure and mortality: Implications from a cohort of 361 662 men. Lancet 1986; ii: 933-6.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-4 4.
4. Jacobs D, Blackburn H, Higgins M et al. Report of the conference on low blood cholesterol: Mortality associations. Circulation 1992; 86: 1046-60.
5. Chen J, Campbell TC, Li J, Peto R. Diet, Life-style and Mortality in China. Oxford: Oxford University Press, 1990.
6. Chen ZM, Peto R, Collins R et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. Br Med J 1991; 303: 276-82.
7. Szatrowski TP, Peterson AV, Shimizu Y et al. Serum cholesterol levels, other risk factors, and cardiovascular disease in a japanese cohort. J Chron Dis 1984; 7: 569-84.
8. Peto R, Yusuf S, Collins R. Cholesterol lowering trials in their epidemiological context (Abstr). Circulation 1985; 72: 451.
9. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994; 308: 367-73.
10. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 1995; 91: 2274-82.
11. Iribarren C, Reed DM, Burchfiel CM, Dwyer JH. Serum cholesterol and mortality. JAMA 1995; 273: 1926-32.
12. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24-33.
13. Bradford RH, Shear CL, Chremos AN et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse effect profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151: 43-9.
14. Keech A, Collins R, MacMahon S, Armitage J, Lawson A, et al for the Oxford Cholesterol Study Group. Three-year follow-up of the Oxford cholesterol study: Assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994; 15: 255-69.
15. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin study (4S). Lancet 1994; 344: 1383-9.
16. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
17. Shepherd J, Cobbe SM, Ford I, et al for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
18. Downs JR, Clearfield M, Weis S, et al for the AFCAPS/ TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22.
19. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
20. Collins R, Keech A, Peto R et al. Cholesterol and total mortality: Need for larger trials. Br Med J 1992; 304: 1689.
21. Cholesterol Treatment Trialists' (CTT) Collaboration. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Am J Cardiol 1995; 75: 1130-4.
22. Oliver MF. Stalins prevent coronary heart disease. Lancet 1995; 346: 1378-9.
23. Oliver MF. Might treatment of hypercholesterolaemia increase non-cardiac mortality? Lancet 1991; i: 1529-31.
24. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: A quantitative review of primary prevention trials. Br Med J 1990; 301: 309-14.
25. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? Br Med J 1992; 304: 431-4.
26. Newman TH, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275: 55-60.
27. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modification of low-density lipoprotein that increases its atherogenicity. N Engl J Med 1989; 320: 915-24.
28. Steinberg D, and Workshop Participants. Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, & Blood Institute Workshop: September 5-6, 1991, Bethesda, Maryland. Circulation 1992; 85: 2338-44.
29. Carew TE, Schwenke DC, Steinberg D. Anti-atherogenic effects of probucol unrelated to its hypercholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit LDL degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the WHHL rabbit. Proc Natl Acad Sci USA 1987; 84: 7725-9.
30. Verlangieri AJ, Bush MJ. Effects of d-α-tocopherol supplementation on experimentally induced primate atherosclerosis. J Am Coll Nutr 1992; 11: 130-7.
31. Williams RJ, Motteram JM, Sharp CH, Gallagher PJ. Dietary vitamin E and the attenuation of early lesion development in modified watanabe rabbits. Atherosclerosis 1992; 94: 153-9.
32. Esterbauer H, Jürgens G, Quehenberger O, Koller E. Autoxidation of human low density lipoprotein: Loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res 1987; 28: 495-509.
33. Dieber-Rotheneder M, Puhl H, Waeg G, Striegl G, Esterbauer H. Effect of oral supplementation with D-α-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. J Lipid Res 1991; 32: 1325-32.
34. Keech A, Collins R, Peto R et al. Vitamin E supplementation inhibits LDL oxidation in patients at risk of coronary disease taking simvastatin or placebo. XI Int Symp Drugs Lip Met 1992; 59.
35. Jandak JM, Steiner M, Richardson PD. Reduction of platelet adhesiveness by vitamin E supplementation in humans. Thromb Res 1988; 49: 393-404.
36. Mahoney CW, Azzi A. Vitamin E inhibits protein kinase C activity. Biochem Biophys Res Comm 1988; 154: 694-7.
37. Diplock A, Xu GL, Yeow CL, Okikola M. Relationship of tocopherol structure to tissue uptake and prostaglandin biosynthesis. Ann NY Acad Sci 1989; 570: 72-84.
38. Janero DR. Therapeutic potential of vitamin E against myocardial ischemic-reperfusion injury. Free Rad Biol Med 1991; 10: 315-24.
39. Jialal I, Grundy SM. Preservation of the endogenous antioxidants in low density lipoprotein by ascorbate but not probucol during oxidative modification. J Clin Invest 1991; 87: 597-601.
40. Gaziano JM, Hennekens CH. Vitamin antioxidants and cardiovascular disease. Curr Opin Lip 1992; 3: 291-4.
41. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328: 1444-9.
42. Rimm EB, Stampfer MJ, AScherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328: 1450-6.
43. Gaziano JM, Manson JE, Branch LG et al. Dietary beta carotene and decreased cardiovascular mortality in an elderly cohort. J Am Coll Cardiol 1992; 19: 377A.
44. Gey KF, Puska P, Jordan P et al. Inverse correlation between plasma vitamin E and mortality from IHD in cross-cultural epidemiology. Am J Clin Nutr 1991; 53: 326S-34S.
45. Riemersma RA, Wood DA, Macintyre CCA, Elton RA, Gey KF, Oliver MF. Risk of angina pectoris and plasma concentrations of vitamins A, C and E and carotene. Lancet 1991; 337: 1-5.
46. Salonen JT, Seppo Y-H, Yamamoto R et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 882-7.
47. Regnström J, Nilsson J, Tornvall P, Landau C, Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992; 339: 1183-6.
48. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: A review of the epidemiological evidence. Nutr Canc 1992; 18: 1-29.
49. Editorial. Antibodies to oxidised LDL in atherosclerosis. Lancet 1992; 339: 899-900.
50. Steinberg D. Antioxidant vitamins and coronary heart disease. N Engl J Med 1993; 328: 1487-9.
51. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-35.
52. Rapola JM, Virtama J, Ripatti S et al. Randomised trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349: 1715-20.
53. Stephens NG, Parsons A, Schofield PM et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-6.
54. Omenn GS, Goodman GE, Thornquist MD et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-5.
55. Hennekens CH, Buring JE, Manson JE et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-9.
56. Greenberg ER, Baron JA, Karagas MR et al. Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation. JAMA 1996; 275: 699-703.
57. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1976; 34: 585-612 and 1977; 35: 1-39.
58. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1976; 34: 585-612 and 1977; 35: 1-39.
59. Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sørensen S, Ömblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340: 1421-5.
60. Early Treatment Diabetic Retinopathy Study (ETDRS) Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. ETDRS Report 14. JAMA 1992; 268: 1292-1300.
61. Aspirin Myocardial Infarction Study Group. A randomized controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980; 243: 661-9.
62. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349-60.
63. UK-TIA Study Group. United Kingdom transient ischaemic attack (TIA) aspirin trial: Interim results. Br Med J 1988; 296: 316-20.
64. Prevention of Atherosclerotic Complications with Ketanserin Trial Group. Prevention of atherosclerotic complications: Controlled trial of ketanserin. Br Med J 1989; 298: 424-30.
65. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results. Br Med J 1985; 291: 97-104.
66. Collins R, Peto R, Gray R, Parish S. Large-scale randomized evidence: Trials and overviews. In: Weatherall D, Ledingham JGG, Warrell DA, eds. Oxford Textbook Of Medicine, Vol. 1. Oxford: Oxford University Press, 1996: 21-32.
67. Lang JM, Buring JE, Rosner B, COok C, Hennekens CH. Estimating the effect of the run-in on the power of the physicians' health study. Stat Med 1991; 10: 1585-93.
68. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-5.
69. Sacks FM, Moyé LA, Davis BR et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 1998; 97: 1446-52.
70. Pedersen TR, Olsson AG, Færgeman O et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1453-60.
71. White SJ, Freedman LS. Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer 1978; 37: 849-57.
72. Grundy SM, Balady GJ, Criqui MH et al. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the american heart association task force on risk reduction. Circulation 1997; 95: 1683-5.
73. Standing Medical Advisory Committee. The Use of Statins. London: Department of Health, 1997. (11061 HCD August 97 (04).
74. Wood DA, DeBacker G, Faergeman O et al. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of european and other societies on coronary prevention. Eur Heart J 1998; 19: 1434-503.
75. Wood D, Durrington P, Poulter N et al. Joint british recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80(Supple 2): S1-S29.
76. EUROASPIRE Study Group. A european society of cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997; 18: 1569-1582.
77. ASPIRE Steering Group. A british cardiac society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events): Principal results. Heart 1996; 75: 334-42.